# David B. Solit

Source: https://onco.cc/people/david-solit/  
OnCo record `david-solit` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Built MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal.

## Summary

David B. Solit is Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. He is known for building MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal. His selected paper reports the mutational landscape of metastatic cancer revealed by prospective clinical sequencing of 10,000 patients. His centre has sequenced tens of thousands of tumours to define actionable alterations, and he continues to study exceptional responders and bladder cancer genomics.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Specialisms: Cancer genomics; MSK-IMPACT; Exceptional responders; Bladder cancer

## Sources

- MSK lab: https://www.mskcc.org/research-areas/labs/david-solit
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Solit%20DB%5BAuthor%5D

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)

---
JSON: https://onco.cc/api/v1/entities/david-solit.json